Mediaboss Marketing

Primary composite first and total major adverse cardiovascular event (MACE) reductions of 23% each shown with VASCEPA in prespecified tertiary and post hoc exploratory analyses of the subgroup of people with diabetes

Key secondary composite first and total MACE reductions of 30% and 29%, respectively, shown with VASCEPA in prespecified tertiary and post hoc exploratory subgroup analyses

Reductions also observed in post hoc exploratory analyses of other composite endpoints, in people with diabetes, and in people with established cardiovascular disease with or without diabetes at baseline

DUBLIN, Ireland and BRIDGEWATER, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that data from the REDUCE-IT study presented during the 80th Scientific Sessions of the American Diabetes Association by Deepak L. Bhatt, M.D., M.P.H., Brigham and Womens Hospital Heart & Vascular Center and Harvard Medical School, showed that administration of 4 g/day of VASCEPA (icosapent ethyl) resulted in significant 23% reductions in both first and total primary composite major adverse cardiovascular events (5-point MACE) in people with diabetes. Reductions of 30% and 29% were observed in both first and total hard (3-point) MACE, the key secondary composite endpoint, respectively. The late-breaking presentation, titled Substantial Cardiovascular Benefit from Icosapent Ethyl in Patients with Diabetes: REDUCE-IT DIABETES was heard on June 13, 2020 at 10:00 am CST.

The leading cause of morbidity and mortality in type 2 diabetes mellitus continues to be cardiovascular disease, especially in those patients who already have established atherosclerotic cardiovascular disease (ASCVD).1 Above normal blood levels of triglycerides (TG) are common in patients with diabetes,2,3 and have been associated with increased ASCVD (30% and 23% higher risk for non-fatal myocardial infarction (MI) and stroke, respectively) in this patient population, despite statin therapy.4

Many of the worlds leading diabetes and cardiovascular disease professional societies, including the American Diabetes Association (ADA) and the American Heart Association (AHA), are working to educate patients and clinicians on the urgent need to identify and manage risk with appropriate therapies. The AHA Scientific Statement on Clinical Management of Stable Coronary Artery Disease in Patients with Type 2 Diabetes Mellitus, published in April of this year, states that icosapent ethyl is the first nonLDL (low-density lipoprotein)-focused lipid therapy to demonstrate cardiovascular benefit and should be considered first-line therapy for patients with T2DM (type 2 diabetes mellitus) and CAD (coronary artery disease) whose triglycerides remain elevated (>135 mg/dL) despite maximally tolerated statin and lifestyle changes.1

People with diabetes are at markedly increased risk of cardiovascular disease, and that intersection has become a target for research and a focus for clinical care, commented Dr. Deepak L. Bhatt, M.D., M.P.H., Executive Director of Interventional Cardiovascular Programs at Brigham and Womens Hospital Heart & Vascular Center and Professor of Medicine at Harvard Medical School, and senior author of the REDUCE-IT DIABETES analyses. In these analyses, we see the substantial impact that icosapent ethyl could have on reducing cardiovascular risks and complications from diabetes.

The prespecified tertiary and post hoc exploratory analyses from the REDUCE-IT study showed that, for the primary composite endpoint of 5-point MACE, time to first event was significantly reduced with VASCEPA versus placebo by 23% (p<0.0001) and total (first and subsequent) events were also reduced by 23% (p=0.0003) in the subgroup of people with diabetes. For the key secondary composite endpoint of 3-point MACE, time to first event was reduced by 30% (p<0.0001) and total events were reduced by 29% (p<0.0001) in the subgroup of people with diabetes. Observed reductions in MACE were supported by further post hoc exploratory analyses of the data across cardiovascular risk category and diabetes status at baseline.

The REDUCE-IT DIABETES subgroup analyses further our understanding of the potential for VASCEPA to benefit people with diabetes, said Steven Ketchum, Ph.D., senior vice president and president, research & development and chief scientific officer, Amarin. The data in our analyses shows consistent outcomes across the at-risk population and supports that VASCEPA can help reduce the already significant burden of cardiovascular disease in people with diabetes.

These REDUCE-IT analyses suggest benefits with VASCEPA that are incremental to those of statin and other therapies with known cardiovascular benefit, including anti-diabetic medications that were well-utilized across people with diabetes, approximately half of whom were taking two or more anti-diabetic therapies.

REDUCE-IT was not specifically powered to examine patient subgroups, therefore p-values presented for these diabetes analyses are nominal and exploratory with no adjustment for multiple comparisons. In addition, while the cardiovascular risk categories of established cardiovascular disease or diabetes plus additional risks were stratification factors, the presence or absence of diabetes in patients with established cardiovascular disease was not. These REDUCE-IT DIABETES results include both prespecified tertiary and post hoc exploratory analyses. Nonetheless, results from these time to first and total events analyses consistently suggest benefit across the various endpoints and recurrent event statistical models. Together, the REDUCE-IT DIABETES first and total events results support the robustness and consistency of the clinical benefit of VASCEPA therapy beyond current standards of medical management in reducing cardiovascular events in patients with diabetes.

Slides from the presentation will be made available on http://www.acc.org.

Financial Disclosure

Funding from Amarin was provided to Brigham and Womens Hospital for Dr. Deepak L. Bhatts work as the REDUCE-IT study chair and global principal investigator.

About Amarin

Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarins lead product, VASCEPA (icosapent ethyl), is available by prescription in the United States, Canada, Lebanon and the United Arab Emirates. Amarin, together with its commercial partners in select geographies, is pursuing additional regulatory approvals for VASCEPA in China, the European Union and the Middle East. For more information about Amarin, visit http://www.amarincorp.com.

About Cardiovascular Risk

The number of deaths in the United States attributed to cardiovascular disease continues to rise. There are 605,000 new and 200,000 recurrent heart attacks per year (approximately 1 every 40 seconds), in the United States. Stroke rates are 795,000 per year (approximately 1 every 40 seconds), accounting for 1 of every 19 U.S. deaths. Cardiovascular disease results in 859,000 deaths per year in the United States.5 In aggregate, this is more than 2.4 million major adverse cardiovascular events per year from cardiovascular disease or, on average, one every 13 seconds in the United States alone.

Controlling bad cholesterol, also known as LDL-C, is one way to reduce a patients risk for cardiovascular events, such as heart attack, stroke or death. However, even with the achievement of target LDL-C levels, millions of patients still have significant and persistent risk of cardiovascular events, especially those patients with elevated triglycerides. Statin therapy has been shown to control LDL-C, thereby reducing the risk of cardiovascular events by 25-35%.6 Significant cardiovascular risk remains after statin therapy. People with elevated triglycerides have 35% more cardiovascular events compared to people with normal (in range) triglycerides taking statins.7,8,9

About REDUCE-IT

REDUCE-IT was a global cardiovascular outcomes study designed to evaluate the effect of VASCEPA in adult patients with LDL-C controlled to between 41-100 mg/dL (median baseline 75 mg/dL) by statin therapy and various cardiovascular risk factors including persistent elevated triglycerides between 135-499 mg/dL (median baseline 216 mg/dL) and either established cardiovascular disease (secondary prevention cohort) or diabetes mellitus and at least one other cardiovascular risk factor (primary prevention cohort).

REDUCE-IT, conducted over seven years and completed in 2018, followed 8,179 patients at over 400 clinical sites in 11 countries with the largest number of sites located within the United States. REDUCE-IT was conducted based on a special protocol assessment agreement with FDA. The design of the REDUCE-IT study was published in March 2017 in Clinical Cardiology.10 The primary results of REDUCE-IT were published in The New England Journal of Medicine in November 2018.11 The total events results of REDUCE-IT were published in the Journal of the American College of Cardiology in March 2019.12 These and other publications can be found in the R&D section on the companys website at http://www.amarincorp.com.

About VASCEPA (icosapent ethyl) Capsules

VASCEPA (icosapent ethyl) capsules are the first-and-only prescription treatment approved by the FDA comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was initially launched in the United States in 2013 based on the drugs initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed over eight million times. VASCEPA is covered by most major medical insurance plans. The new, cardiovascular risk indication for VASCEPA was approved by the FDA in December 2019.

Indications and Limitation of Use

VASCEPA is indicated:

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

Important Safety Information

Key clinical effects of VASCEPA on major adverse cardiovascular events are included in the Clinical Studies section of the prescribing information for VASCEPA, as set forth below:

Effect of VASCEPA on Time to First Occurrence of Cardiovascular Events in Patients with Elevated Triglyceride levels and Other Risk Factors for Cardiovascular Disease in REDUCE-IT

n (%)

n (%)

(17.2)

(22.0)

(0.68, 0.83)

(11.2)

(14.8)

(0.65, 0.83)

(6.1)

(8.7)

(0.58, 0.81)

(5.3)

(7.8)

(0.55, 0.78)

(4.3)

(5.2)

(0.66, 0.98)

(2.6)

(3.8)

(0.53, 0.87)

(2.4)

(3.3)

(0.55, 0.93)

[2] Determined to be caused by myocardial ischemia by invasive/non-invasive testing and requiring emergent hospitalization.

FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT http://WWW.VASCEPA.COM.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the potential impact of VASCEPA in various clinical uses. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties associated generally with research and development and clinical trials such as further clinical evaluations failing to confirm earlier findings. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Amarins forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate.

Availability of Other Information About Amarin

Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarins investor relations website and may include social media channels. The contents of Amarins website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact Information

Investor Inquiries:Elisabeth SchwartzInvestor RelationsAmarin Corporation plcIn U.S.: +1 (908) 719-1315investor.relations@amarincorp.com (investor inquiries)

Lee M. SternSolebury TroutIn U.S.: +1 (646) 378-2992lstern@soleburytrout.com

Media Inquiries:Alina KolomeyerCommunicationsAmarin Corporation plcIn U.S.: +1 (908) 892-2028PR@amarincorp.com (media inquiries)

___________________________________

1 Arnold SV, Bhatt DL, Barsness GW, et al. Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation. 2020;141(19):e779e806. doi:10.1161/CIR.0000000000000766

2 Fan W, Philip S, Granowitz C, Toth PP, Wong ND. Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014. Diabetes Care. 2019;42(12):23072314.

3 Rana JS, Liu JY, Moffet HH, et al. Metabolic dyslipidemia and risk of coronary heart disease in 28,318 adults with diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl. Am J Cardiol. 2015;116:1700-1704.

4 Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab. 2019;21(2):366371.

5 American Heart Association. Heart Disease and Stroke Statistics2020 Update: A Report From the American Heart Association. Circulation. 2020;141:e139e596.

6 Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330-343.

7 Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol. 2016;118:138-145.

8 Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7(15):e008740.

9 Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease - New insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547-563.

10 Bhatt DL, Steg PG, Brinton E, et al., on behalf of the REDUCE-IT Investigators. Rationale and Design of REDUCEIT: Reduction of Cardiovascular Events with Icosapent EthylIntervention Trial. Clin Cardiol. 2017;40:138-148.

11 Bhatt DL, Steg PG, Miller M, et al., on behalf of the REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22.

12 Bhatt DL, Steg PG, Miller M, et al., on behalf of the REDUCE-IT Investigators. Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles. J Am Coll Cardiol. 2019;74:1159-1161.

Visit link:
VASCEPA (icosapent ethyl) Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified and Post Hoc Subgroup Analyses of...

Dublin, June 15, 2020 (GLOBE NEWSWIRE) -- The "Pandemic Outbreaks in the Past Decade: A Research Overview" report has been added to ResearchAndMarkets.com's offering.

Pandemics are outbreaks of disease that become widespread by the transmission of human-to-human infection. Throughout recent history, disease outbreaks and pandemics include Spanish flu, Hong Kong flu, SARS, H7N9, Ebola, and Zika. The main features of a pandemic include broad geographic spread, disease movement, novelty, intensity, high attack rates, and explosivity, limited population immunity, infectiousness, and contagiousness. Pandemics adversely have affected the health of the global population and destabilized the world's economies, social infrastructures, and both geopolitical and natural environments.

Human history has experienced major pandemics such as smallpox, cholera, plague, dengue, AIDS, influenza, extreme acute respiratory syndrome (SARS), West Nile disease, and tuberculosis. Influenza pandemics are sporadic yet frequent phenomena. Since the 1500s, influenza pandemics have occurred about three times a century, or about every 10 to 50 years. Three influenza pandemics occurred in the 20th century: 1918 influenza pandemic (Spanish flu), 1957-1958 pandemic (Asian flu), and the 1968 pandemic (Hong Kong flu). Each pandemic harmed human life and economic growth. For example, the 1918 influenza pandemic killed more than 20 million people worldwide. The World Health Organization (WHO) cites that pandemic as the deadliest in world history.

This Report Includes:

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Introduction to Pandemics

Chapter 3 H1N1 Influenza (Swine Influenza)

Chapter 4 Ebola Virus Disease

Chapter 5 Middle East Respiratory Syndrome

Chapter 6 Coronavirus Disease 2019 (SARS-CoV-2)

Chapter 7 Lessons Learned from History

Chapter 8 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/jo3r3i

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Original post:
A Research Overview of Pandemic Outbreaks in the Past Decade 2010-2020 - GlobeNewswire

By: Editorial | Updated: June 12, 2020 3:11:36 pm Clearly, the J&K administrations ideas of democratic governance are very different from what the Constitution of India promises.

The New Media Policy of the Jammu & Kashmir administration resembles 1984 in its 53 pages of rules and regulations on what is news, the setting up of a mechanism for monitoring of fake news, conditions newspapers need to meet in order to be empanelled and under what circumstances they will be de-empanelled. The J&K Directorate of Information and Public Relations may not have George Orwells vocabulary but the framers of this policy have managed to provide a remarkably clear picture of the media they want journalists and news organisations answerable not to their readers, nor even to their editors, but to government bureaucrats and security officials, who will have the powers to decide which news item is fake or anti-national; and with these determinations, to further decide the economic viability of a newspaper through the carrots and sticks of government advertisements. Officials will sit in judgement on journalistic ethics and issues of plagiarism. All this for building a genuinely positive image of the government based on performance, and to build public trust and increase public understanding about the Governments roles and responsibilities. In case anyone missed it, a Goebbelsian reminder is provided under the separate sub-head of Repetition: Wherever possible a repetitive schedule shall be devised for placement of important information to ensure it receives public consideration.

Clearly, the J&K administrations ideas of democratic governance are very different from what the Constitution of India promises. Though the government talks of bringing equality to the people of the former state, its heavy-handed approach has ensured that the people of J&K have not yet been given the opportunity to voice their opinion on the August 5, 2019 decision to strip the erstwhile state of its special status under Article 370, and bifurcate it into two union territories. Political leaders were jailed and a former chief minister is still under house arrest. The internet has still not been restored to its full strength. Restrictions on the media ensured that there was no first draft of history from the ground. At a time when democratic political voices remain missing in J&K, the new media policy is a further affront, intended to keep control of the narrative of J&K.

An indication of the new normal for journalism in and about J&K that the government wants to create came last month, when it booked photographer Masrat Zehra and journalist-author Gowhar Geelani under anti-terror laws for social media posts, and registered a case over a report in a national newspaper, summoning its Srinagar correspondent for questioning. A free media can help the government take the right actions more effectively than sunshine stories. The government should enable an atmosphere for free and fearless journalism, instead of creating policies to obstruct and prevent it.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Opinion News, download Indian Express App.

The Indian Express (P) Ltd

Go here to read the rest:
Ministry of Truth - The Indian Express

Android 11 has a bunch of goodies.

Google released the first public beta of Android 11 this week. There are plenty of under-the-hood features for developers to take advantage of, but regular users aren't left out either. You can install the first beta right now as long as you have a Pixel 2 or newer. I signed up to participate in the beta program on a Pixel 4 XL ($799 at Amazon) and have been digging through the update.

We're big fans of the new quick controls page that's easy to access and incredibly helpful, along with the revamped media controls, while app suggestions and Bubbles will take some getting used to.

While we're sure Google has more Android 11 surprises in store for us, here are five features we have tried and know you'll love when it's released later this year.

Android 11's quick controls are my new favorite controls.

The first thing you should do after installing Android 11, whether it's the beta or when it's officially released, is long-press the power button on your phone to bring up the new quick controls screen. On the Pixel, at least, this screen gives you power control options along the top, provides shortcuts to your Google Pay cards and boarding passes, and then below that you'll find my favorite feature of Android 11 -- quick controls for smart home devices.

My phone automatically picked a few devices I've linked to Google Assistant, like the Nest thermostat in my office and my Nest video doorbell. I can even view a livestream from my doorbell directly on this screen, without having to open the Nest app (which is slow and a pain to use). It's great.

You can add or remove smart home devices from this grid by tapping on the menu button and selecting add or edit controls.

Now playing: Watch this: Android 11: What's new in the public beta

7:11

Bubbles look all sorts of useful.

Remember Bubbles? This feature was supposed to be part of Android 10, but Google pulled it at the last minute. Well, they're back.

Bubbles are similar to Facebook Messengers "chat heads" feature. When activated, a small avatar -- or Bubble -- on your screen that is visible no matter what app you're using. Tap on the avatar and it will open a small window for you to read and send new messages in that thread, without fully opening the app. You can drag the Bubble around your screen, or drag it to the bottom of the screen to delete it.

In the first public beta, the only app that seems to work with Bubbles right now is Facebook Messenger. Even then, it doesn't fully work. We expect Google will work out the kinks before the full Android 11 release.

In order to use Bubbles for a conversation, there will be a small Bubbles icon in the bottom-right corner of the notification. Tapping on it will immediately enable Bubbles for that thread.

Another way to activate Bubbles for specific conversations is to long-press on its notification and mark it as a priority. Doing so will not only turn on Bubbles for that thread, but it will also allow that conversation to break through Do Not Disturb ensuring you don't miss any messages.

App suggestions on the home screen are new.

Immediately after installing the public beta and unlocking my Pixel 4 XL, I was greeted with an option to enable app suggestions on the home screen. Unsure of what exactly that was, I reluctantly agreed. Turns out, it's pretty darn cool.

Previously, Android made suggestions in the app drawer of apps it thought you'd want to use, depending on the time of day and other mysterious factors. In Android 11, there's now a row of app suggestions on the bottom of your home screen where your main app dock would normally show up.

The apps have a glowing border around them, and frequently change when you return to your home screen as you use your phone. You can long-press on any of the app icons to pin that suggestion to your home screen.

You can also block apps from showing up as suggestions if you don't want something like Gmail showing up even though you use a different email app.

To access App Suggestions and tailor how it works for you long-press on your home screen and select Home Settings then Suggestions. There you can control suggestions in the app drawer and on the home screen or block apps from showing up on the list.

The new media controls sure look nice.

In the blog post announcement for the Android 11 public beta, Google showed off a new music control interface that looked amazing. Instead of playback controls looking more like a pending notification, they're placed in the Quick Settings panel at the top of your screen. And when you interact with them, there's a new option to control where the music is playing.

For example, if you have Google's new Pixel Buds 2 and a Nest Hub ($89 at Crutchfield), you can quickly switch between the two devices with a couple of taps.

If you install the Android 11 beta, the feature is nowhere to be found when you begin playing music. Don't get discouraged -- it's there, but it's hidden.

You'll need to enable Developer Options on your phone by opening the Settings app and going to About phone. Scroll to the bottom of the screen where you'll find Build Number. Tap on it until you see a small notification show up saying something like "Congrats! You're now a developer."

Next, we'll need to go into Developer Options in Settings > System. Once there, find Media resumption, turn it on, and then reboot your phone.

The next time you start playing some music, the new media controls will be available.

You can finally record your screen with an official Google tool.

Screenshots are a quick and easy way to capture something on your screen, but there are times when a recording is better suited to the task at hand. For example, if you want to show off your gaming skills, or highlight the steps to reproduce a bug -- screen recording FTW!

You can find the Screen Record tool in the Quick Settings panel after installing Android 11. If it's not visible, tap on the pencil icon to add it to your panel.

Now playing: Watch this: Galaxy A51 review: A worthy Android iPhone SE alternative

3:54

Tap on the Screen Record icon and select whether you want your microphone to record audio and if you want your touch interactions to be highlighted in the video. To stop recording, tap the Screen Record notification. The video will be saved to your camera roll where you can then edit and share the recording.

We're going to keep digging into Android 11 and see what other goodies are hidden or added throughout the rest of the beta process. In the meantime, if you just can't wait for Android 11 to launch later this year, you can install it right now.

See the article here:
5 best new features in Android 11 and how you'll use them - CNET

Scott Jennings, Opinion contributor Published 6:14 a.m. ET June 9, 2020 | Updated 9:20 a.m. ET June 9, 2020

Mayor Greg Fischer had said he wasn't attending protests to avoid being a distraction. On Tuesday, he spoke and answered questions from the crowd. Louisville Courier Journal

Eighty percent of Americans in this weekends NBC News/Wall Street Journal poll said the United States is out of control. The easy analysis will revolve around President Donald Trumps handling of recent crises, but depending on your political perspective, you might think things are spiraling for different reasons.

Take Louisville Mayor Greg Fischer, for instance, whose administration is out of control for the first time since taking office nine years ago. His performance has been shaky at best in the wake of the Breonna Taylor and David McAtee killings, and his constituents are letting him know.

WFPL reported Fischer was confronted by a group of young African Americans on Sunday who asked pointedly: Why were you silent for two months on Breonna Taylors murder? Another leveled a biting accusation: Youve been using us for photo ops for years.

And Fischers recent meeting with Louisvilles police officers didnt end well, either. Dozens of cops walked out on him because they feel completely unsupported and disrespected, according to Fraternal Order of Police president Ryan Nicholas.

Oof. You can feel the confidence draining out of City Hall, but at least Fischer succeeded in uniting the demonstrators and police on something.

More: Fairness Campaign yanks support for Mayor Greg Fischer after police 'gas his own city'

Kentucky Gov.Andy Beshear must feel a bit out of control, too. After months of scolding Kentuckians with his folksy-yet-aggressive yall cant be doing that edicts and enjoying high approval for it, he did a complete 180 when thousands took to Louisvilles streets in full violation of his ban on mass gatherings. After essentially confining Kentuckians to their homes for months, Beshear praised the demonstrators for their supposed adherence to anti-COVID-19guidelines.

You've got better compliance in these demonstrations than we do just about anywhere, Beshear said. Out loud. With a straight face.

For any Kentuckian who lost a job, turned their home into a school, missed their graduation, couldnt hold a funeral or comfort a dying loved one, put off a wedding, or shut down a restaurant, Beshear thinks the demonstrators are doing a better job than you in preventing coronavirus spread.

Beshears contemptuous attitude is made all the more laughable by his repeated claims to be done with politics in his effort to save lives. He sold out his entire message on coronavirus to curry favor with Louisvilles demonstrators and rioters, despite the public health scoldings hes given Kentuckians who dared question him.

But the governor is now boxed in. If theres a COVID- spike because of the demonstrations, Beshears pandering will look even more foolish. If there isnt, a whole bunch of Kentuckians aregoing to ask: Whatwere we doing for the last several months, dude?

Beshear, in full defensive mode to head off the same pressure Fischer is under, pandered further last week by announcing that he favored removal of the Jefferson Davis statue from Kentuckys Capitol Rotunda.

Joe Gerth: Jefferson Davis statue must be removed from Kentucky Capitol. NOW.

If Beshear really cared about removing the symbol that divides us, it would already be gone. It sits outside of his office, after all, and he could have had it removed any day since taking office. (And dont give me any static about the Historical Properties Commission. They guy just put 40% of Kentucky out of work via executive order and closed every church. If he wants to move a statue, he can move a statue.)

His father, former Gov.Steve Beshear, left it in the Rotunda for a full eight years.

But the clan Beshear saved old Jeff Davis for a political rainy day, which has assuredly come. The governor is not worried about the symbolism, of course, just the politics. (For what its worth, Kentuckys top Republican, Sen.Mitch McConnell, has steadfastly favored removal since 2015, as has this columnist).

These marches have made for fascinating politics. Defund the police is making its way rapidly into mainstream Democratic thought and comes on the heels of Joe Biden telling black Americans they arent actually black unless they support him.

And many conservatives have been wondering what would happen if people marched for different reasons, perhaps ones not so en vogue with the mainstream media?

Scott Jennings, columnist(Photo: photo courtesy Scott Jennings)

What if there were pro-life or pro-Second Amendment marches? What if Donald Trump held a campaign rally?

What would the media and Democratic political narrative be? Would they imply these righteous causes had imbued their supporters with coronavirus immunity, as Beshear and other Democratic leaders have done for police and race demonstrators?

Of course not. They would label them selfish grandma killers.

Interestingly, demonstrators at the White House this weekend were photographed with anti-Trump bunker bitch signs, which has nothing to do with policing or racism. Im no doctor, but their righteous cause immunity may not be as strong as they think.

News: Following fatal shootings, Fischer announces 'top-to-bottom' review of police department

Indeed, the world feels out of control to many conservatives, too. We mourn and demand justice for George Floyd. We want police reform. And we want jobs for black adults, over half of whom are out of work thanks in large party to the COVID-19 lockdown. We pray for the health and safety of demonstrators who are now at risk for contracting coronavirus, which has disproportionately affected African Americans already.

But we want one more thing: an end to the doublespeak and double standards that define the coverage and treatment of our national political discourse.

Scott Jennings is a Republican adviser, CNN political contributor, and partner at RunSwitch Public Relations. He can be reached atScott@RunSwitchPR.comor on Twitter@ScottJenningsKY.

Read or Share this story: https://www.courier-journal.com/story/opinion/2020/06/09/breonna-taylor-protests-greg-fischer-andy-beshear-out-control/5318225002/

Read the rest here:
Opinion: What's 'out of control' is Greg Fischer's administration and Andy Beshear - Courier Journal